Evaluation of the Presence of LGL in the Different T-Cell Subsets
Patients and Controls . | Lymphocytes (per μL) . | LGL4-150 . | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | . | PBL . | CD4+ . | CD4− . | CD4+CD57− . | CD4−CD57− . | LGL4-151 . | . | . | . | . | ||||||||||
. | . | % . | μL . | % . | μL . | % . | μL . | % . | μL . | % . | μL . | CD4+CD57+ . | CD4−CD57+ . | . | . | . | . | . | . | ||
. | . | . | . | . | . | . | . | . | . | . | . | % . | μL . | % . | μL . | . | . | . | . | . | . |
ROPI | 2,703 | 24 | 649 | 7 | 104 | 23 | 138 | 0 | 0 | 8 | 26 | 64 | 104 | 41 | 112 | ||||||
GEGU | 1,861 | 7 | 130 | 2 | 17 | 10 | 60 | 1 | 7 | 4 | 7 | 8 | 10 | 13 | 53 | ||||||
LOME | 1,251 | 37 | 463 | 11 | 64 | 30 | 146 | 1 | 5 | 7 | 11 | 56 | 59 | 40 | 135 | ||||||
MAGHI | 1,860 | 30 | 558 | 7 | 54 | 45 | 167 | 0 | 0 | 16 | 35 | 29 | 54 | 85 | 132 | ||||||
Controls | 2,009 ± 399 | 14.3 ± 2.2 | 247.6 ± 71.3 | 1.2 ± 1.2 | 12 ± 10 | 29 ± 11 | 179 ± 66 | — | — | — | — | — | — | — | — |
Patients and Controls . | Lymphocytes (per μL) . | LGL4-150 . | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | . | PBL . | CD4+ . | CD4− . | CD4+CD57− . | CD4−CD57− . | LGL4-151 . | . | . | . | . | ||||||||||
. | . | % . | μL . | % . | μL . | % . | μL . | % . | μL . | % . | μL . | CD4+CD57+ . | CD4−CD57+ . | . | . | . | . | . | . | ||
. | . | . | . | . | . | . | . | . | . | . | . | % . | μL . | % . | μL . | . | . | . | . | . | . |
ROPI | 2,703 | 24 | 649 | 7 | 104 | 23 | 138 | 0 | 0 | 8 | 26 | 64 | 104 | 41 | 112 | ||||||
GEGU | 1,861 | 7 | 130 | 2 | 17 | 10 | 60 | 1 | 7 | 4 | 7 | 8 | 10 | 13 | 53 | ||||||
LOME | 1,251 | 37 | 463 | 11 | 64 | 30 | 146 | 1 | 5 | 7 | 11 | 56 | 59 | 40 | 135 | ||||||
MAGHI | 1,860 | 30 | 558 | 7 | 54 | 45 | 167 | 0 | 0 | 16 | 35 | 29 | 54 | 85 | 132 | ||||||
Controls | 2,009 ± 399 | 14.3 ± 2.2 | 247.6 ± 71.3 | 1.2 ± 1.2 | 12 ± 10 | 29 ± 11 | 179 ± 66 | — | — | — | — | — | — | — | — |
The percentage of LGL was evaluated morphologically, while the number of LGL/μL was calculated on the basis of the number of cells with the indicated phenotype.
The number of LGL/μL in the two T-cell subpopulations was deduced by respectively subtracting from the number of LGL found in the CD4+ and CD4− subsets the number of LGL found in the CD4+CD57− and CD4−CD57− cell populations. The percentage of LGL was calculated on the basis of the number of total CD4+CD57+ and CD8+CD57+ circulating lymphocytes.